| Godina | Naslov | Autor(i) | Tip rezultata | Mp-kat. |
| 2024 | Autophagy regulation in peripheral blood mononuclear cells of patients with myasthenia gravis | Milošević, Emina   ; Paunović, Verica ; Stamenković, Marina M. ; Perić, Stojan ; Basta, Ivana ; Božović, Ivo ; Stević, Zorica ; Trajković, Vladimir | Conference Paper | |
| 2023 | Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT) | Sacca, Francesco; Barnett, Carolina; Vu, Tuan; Perić, Stojan Z. ; Phillips, Glenn A.; Zhao, Sihui; Qi, Cynthia Z.; Gelinas, Deborah; Chiroli, Silvia; Verschuuren, Jan JGM | Naučni članak | 21aM21a - Vodeći međunarodni časopis kategorije M21a |
| 2022 | Efgartigimod improved quality-of-life in gMG: a randomised, double-blinded, placebo-controlled, phase 3 trial (ADAPT) | Sacca, Francesco; Barnett-Tapia, C.; Vu, T.; Peric, Stojan Z. ; Phillips, Glenn A.; Zhao, Sihui; Gelinas, D.; Chiroli, Silvia; Verschuuren, J. | Konferencijski rad | |
| 2026 | European S2k guidelines on management of autoimmune blistering diseases in children and adolescents | Nanda, A; ...; Nikolic, M; ...; (broj, koautora 32) | Naučni članak | 21aM21a - Vodeći međunarodni časopis kategorije M21a |
| 2024 | Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT plus ): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis | Howard, Jr James F.; ...; Perić, Stojan Z. ; ...; (broj koautora 17) | Article | |
| 2026 | Plasma miR-150-5p as a biomarker for immunosuppressive therapy response in acetylcholine receptor positive myasthenia gravis: a long-term prospective longitudinal study | Garai, Nemanja ; Madić, Sanja ; Ivanović, Vukan ; Palibrk, Aleksa; Pešović, Jovan ; Brkušanin, Miloš ; Basta, Ivana ; Perić, Stojan ; Savić-Pavićević, Dušanka | Article | |
| 2021 | Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trial | Howard, James; ...; Perk, Stojan; ...; (broj, koautora 16) | Article | |
| 2024 | Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE) : a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial | Allen, Jeffrey A; ...; Basta, Ivana Z; ...; (broj, koautora 26) | Article | |